Press Release|CMBS
View PDF

KBRA Affirms All Ratings for BX 2025-BIO3

11 Feb 2026   |   New York

Contacts

KBRA affirms all outstanding ratings for BX 2025-BIO3, a CMBS single-borrower transaction. The affirmations follow a surveillance review of the transaction, which has exhibited stable performance since securitization.

The transaction collateral is a $535.0 million portion of a $765.0 million non-recourse, first lien mortgage loan backed by seven properties and leasehold interest in one property, which together comprise three office buildings (59.8% of loan amount) and five life science lab/office buildings (40.2%). The portfolio comprises a total of 1.3 million sf of life science and office space located within four of the largest life science markets in the US across three states, Massachusetts (two properties, 47.5%), California (five, 45.0%), and Washington (one, 7.4%). The fixed-rate loan has a five-year term and requires monthly interest-only payments that are based on a coupon of 6.65%. The sponsor of the borrower is BioMed Realty, L.P., which is a portfolio company of The Blackstone Group (NYSE: BX).

KBRA analyzed the cash flow for the properties utilizing information from the trustee and servicer to determine KNCF. The analysis produced a KNCF of $62.6 million and a KBRA value of $769.8 million ($601 per sf). The resulting in-trust KLTV is 99.4%, compared to 97.4% at securitization. KBRA assigns a KPO of Perform on the loan.

To access ratings and relevant documents, click here.

Click here to view the report.

Related Publication

Methodologies

Disclosures

Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above.

A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here.

Information on the meaning of each rating category can be located here.

Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com.

About KBRA

Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan’s Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S.

Doc ID: 1013439